MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. was honored to be selected as a Poster Finalist at the Schizophrenia International Research Society (SIRS) 2025 Congress this week. Our presentation on ML-007, an investigational treatment for schizophrenia, sparked meaningful discussions on its potential impact.   The congress provided an excellent platform for our team to engage with peers and contribute to the evolving dialogue on advancing schizophrenia therapies. We are inspired by the collaborative spirit and collective drive to enhance treatment options   Here are some snapshots from our team’s time in Chicago.   #SIRS2025 #SchizophreniaResearch #Schizophrenia

April is National Autism Awareness Month – and today, April 2nd, we recognize Autism Awareness Day. It’s a time to raise understanding and support for individuals living with autism spectrum disorder (ASD) and those advocating on their behalf. This month, we aim to amplify the voices of individuals with ASD and the organizations that advocate on their behalf. At MapLight Therapeutics, Inc., we are committed to addressing the unique challenges of ASD. Our research focuses on understanding the neurodevelopmental intricacies of ASD to develop potentially groundbreaking therapies tailored to the diverse needs of those affected. Our goal is to offer new therapeutic options for those significantly impacted by the core symptoms of ASD, for which there are currently no FDA-approved medications. Explore how we're working to change the future of autism care: https://lnkd.in/gxwYtiwy #AutismAwarenessMonth #InnovationForAutism #Autism #AutismAwareness

Looking for a career where your work makes a real impact? MapLight Therapeutics, Inc. is on the hunt for passionate individuals across multiple departments to contribute to groundbreaking advancements in neuroscience. Don’t see the perfect role for you? Submit your resume to be considered for future opportunities. Explore open positions here: https://lnkd.in/eYPT63Mt #CareersInScience #NowHiring #JoinMapLight #LifeAtMapLight

Meet Bea Goder-Reiser, our Senior Specialist in People Operations. From onboarding new hires to fostering an exceptional workplace culture, Bea plays a pivotal role in making MapLight Therapeutics, Inc. a great place to work. Thank you, Bea, for your dedication to our team!  #EmployeeSpotlight #PeopleOperations #LifeAtMapLight

MapLight Therapeutics, Inc. is seeking participants for the IRIS research study, aimed at understanding if an investigational drug can improve social communication difficulties in individuals with autism spectrum disorder. Difficulties with communication and social interaction are common challenges faced by those with autism. This study presents an opportunity to potentially enhance their ability to communicate and interact socially. Eligibility Criteria: ✅Age between 12 to 17 years ✅Diagnosed with autism spectrum disorder ✅Must have a parent/guardian or study partner to assist during the study and attend clinic visits Study Details: ⭐️No cost to participate ⭐️Compensation for time and travel may be provided For more information and to see if your child qualifies, please visit our website. https://lnkd.in/e9YaUN6H #AutismResearch #ClinicalTrials #IRISClinicalTrial

MapLight Therapeutics, Inc. is heading to Chicago to participate in the Schizophrenia International Research Society (SIRS) 2025 Congress on March 30. We will be presenting data from our latest research on ML-007 for the potential treatment of schizophrenia. Our team is looking forward to discussing the scientific advancements and implications of our findings. Join us to explore how our approach has the potential to shape the future of schizophrenia treatment. Learn more about this meeting by visiting the SIRS website. https://lnkd.in/e3sjS28g #SIRS2025 #SchizophreniaResearch #Schizophrenia

Ever wondered what it’s like to work at MapLight Therapeutics, Inc.? Our LinkedIn Life page offers a peek into our culture, the people, and the passion behind our mission. Check it out and see why we think it’s a remarkable place to work! https://lnkd.in/e-4Hxr9g #InsideMapLight #Culture #LifeAtMapLight

This month, we’re excited to officially welcome Terry Ryan to the MapLight Therapeutics, Inc. team! Terry has worked with us for over a year as a contractor, and we are glad to have him on board as a full time employee. Join us in giving him a warm welcome in the comments! #LifeAtMapLight #NewHire #TeamWelcome

March is Developmental Disabilities Awareness Month – a time to advocate for inclusivity and progress. At MapLight Therapeutics, Inc., we’re committed to research that has the potential to create new treatment options for conditions such as autism spectrum disorder. Together, we can foster greater understanding and support for individuals with developmental disabilities. Share this post with your network to help spread awareness! #DevelopmentalDisabilities #AutismAwareness

This Women’s History Month, MapLight celebrates the women in biotech and neuroscience whose trailblazing attitude and relentless spirit drive our mission forward. A special thank you to the incredible women at MapLight Therapeutics, Inc. – we appreciate you, and your contributions make a difference every day. Who is a woman in the biotech industry that inspires you? Tag them in the comments below for recognition. ⬇️ #WomensHistoryMonth #WomenInScience #InspirationInAction